Inozyme Pharma INZY

$ 2.76 -2.13%

Quarterly report 2024-Q3
added 11-05-2024

Inozyme Pharma Balance Sheet 2011-2025 | INZY

Annual Balance Sheet Inozyme Pharma

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	11.1 M	-28 M	-19.9 M	-28 M	-31.6 M	-36 M	-	-	-	-	-	-	-
Long Term Debt	44.8 M	4.14 M	2.64 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	910 K	816 K	731 K	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	1.29 M	77.9 M	55 M	-	-	-	-	-	-	-
Total Current Liabilities	14.7 M	14.7 M	11.6 M	9.97 M	-	-	-	-	-	-	-	-	-
Total Liabilities	60.4 M	20.8 M	14.3 M	11.3 M	81.2 M	57.4 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-286 M	-215 M	-148 M	-91.1 M	-34.7 M	-14.9 M	-	-	-	-	-	-	-
Total Assets	201 M	139 M	124 M	169 M	47.9 M	43.5 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	34.6 M	32.9 M	23.3 M	28 M	-	-	-	-	-	-	-	-	-
Book Value	140 M	118 M	109 M	158 M	-33.2 M	-13.9 M	-	-	-	-	-	-	-
Total Shareholders Equity	140 M	118 M	109 M	158 M	-33.2 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Inozyme Pharma

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	42.1 M	45.3 M	45 M	44.8 M	32.1 M	31.9 M	24.2 M	4.14 M	4.07 M	2.24 M	2.44 M	2.64 M	2.83 M	3.01 M	3.19 M	1.29 M	1.29 M	1.29 M	1.29 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	60.6 M	61.3 M	58.1 M	60.4 M	45.5 M	45.3 M	38.4 M	20.8 M	19.2 M	12.8 M	14.7 M	14.3 M	11.8 M	9.98 M	10 M	11.3 M	11.3 M	11.3 M	11.3 M	3.24 M	3.24 M	3.24 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-361 M	-336 M	-309 M	-286 M	-264 M	-248 M	-232 M	-215 M	-196 M	-180 M	-165 M	-148 M	-129 M	-115 M	-102 M	-91.1 M	-91.1 M	-91.1 M	-91.1 M	-34.7 M	-34.7 M	-34.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	143 M	156 M	177 M	201 M	206 M	151 M	142 M	139 M	154 M	162 M	109 M	124 M	138 M	148 M	159 M	169 M	169 M	169 M	169 M	47.9 M	47.9 M	47.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	24.6 M	15.2 M	20.6 M	34.6 M	46.9 M	40.8 M	49 M	32.9 M	44 M	62.6 M	31.9 M	23.3 M	27.2 M	26.2 M	16.5 M	28 M	28 M	28 M	28 M	31.6 M	31.6 M	31.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	82.8 M	94.4 M	119 M	140 M	160 M	106 M	103 M	118 M	135 M	149 M	94.2 M	109 M	126 M	138 M	149 M	158 M	158 M	158 M	158 M	44.7 M	44.7 M	44.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	82.8 M	94.4 M	119 M	140 M	160 M	106 M	103 M	118 M	135 M	149 M	94.2 M	109 M	126 M	138 M	149 M	158 M	158 M	158 M	158 M	-33.2 M	-33.2 M	-33.2 M	-18.8 M	-13.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency